Johnson & Johnson beats profit estimates on pharma strength, raises sales outlook

Johnson & Johnson beats profit estimates on pharma strength, raises sales outlook

Johnson & Johnson reported a 41.8per cent rise in second-quarter profit on Tuesday, helped by its pharmaceuticals business.

The Johnson & Johnson logo is displayed on a screen on the floor of the NYSE in New York
The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 29, 2019. REUTERS/Brendan McDermid

REUTERS: Johnson & Johnson hiked its full-year operational sales forecast as strong demand for its cancer drugs Darzalex and Imbruvica helped it beat estimates for second-quarter profit on Tuesday.

Overall strength in J&J's pharmaceuticals unit, bolstered by recent approvals for new treatments such as its cancer drug Erleada also helped drive its earnings beat.

Pharmaceutical sales rose 1.7per cent to US$10.53 billion, above analysts' estimates of US$10.27 billion, according to three analysts polled by Refinitiv.

The company raised its operational sales forecast for 2019 to US$82.4 billion to US$83.2 billion, from a prior range of US$82 billion to US$82.8 billion.

The diversified healthcare company, the first major U.S. drugmaker to report second-quarter results, said net earnings rose to US$5.61 billion, or US$2.08 per share, from US$3.95 billion, or US$1.45 per share, a year earlier.

Excluding items, the company earned US$2.58 per share, beating analysts' expectations for US$2.46 per share, according to IBES data from Refinitiv.

The company reported a quarterly litigation expense of US$409 million, down from US$703 million a year earlier.

Sales fell 1.3per cent to US$20.56 billion but came in ahead of estimates for US$20.29 billion.

(Editing by Bernadette Baum)

Source: Reuters

Bookmark